axialHealthcare Closes Series C Funding Round

We represented axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.

You Also May Be Interested In:

  • Representation of Twin River Worldwide Holdings, Inc. (NYSE: TRWH) in its definitive agreement to acquire Jumer’s Casino & Hotel, from Delaware North Companies Gaming & Entertainment, Inc., for $120 million in cash

     

    We represented Twin River Worldwide Holdings, Inc. in its definitive agreement to acquire Jumer's Casino & Hotel, from Delaware North...
    Client Type: Public Company
  • Representation of Southern Ear, Nose, and Throat and Allergy (SENTA) Partners, an ENT and allergy management services organization backed by Shore Capital Partners, in its affiliation with Atlanta Allergy & Asthma, the largest allergy practice in Georgia

    We represented Southern Ear, Nose, and Throat and Allergy (SENTA) Partners, an ENT and allergy management services organization backed by...
    Client Type: Private Company
  • Representation of Truxton Trust, a subsidiary of financial holding company, Truxton Corporation (OTCPK: TRUX), in the sale of $15 million aggregate principal amount of fixed-to-floating rate subordinated notes due in 2030

    We represented Truxton Trust in the sale of $15 million aggregate principal amount of fixed-to-floating rate subordinated notes due in...
    Client Type: Public Company